Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Exchange Rate Effect (2023 - 2025)

NewAmsterdam Pharma's Exchange Rate Effect history spans 3 years, with the latest figure at -$60000.0 for Q4 2025.

  • For Q4 2025, Exchange Rate Effect rose 99.24% year-over-year to -$60000.0; the TTM value through Dec 2025 reached $12.8 million, up 287.58%, while the annual FY2025 figure was $12.8 million, 287.58% up from the prior year.
  • Exchange Rate Effect for Q4 2025 was -$60000.0 at NewAmsterdam Pharma, down from $222000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $8.8 million in Q2 2025 and bottomed at -$7.9 million in Q4 2024.
  • The 3-year median for Exchange Rate Effect is $81000.0 (2025), against an average of $917416.7.
  • The largest annual shift saw Exchange Rate Effect plummeted 252.05% in 2024 before it skyrocketed 1070.96% in 2025.
  • A 3-year view of Exchange Rate Effect shows it stood at $5.2 million in 2023, then tumbled by 252.05% to -$7.9 million in 2024, then surged by 99.24% to -$60000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Exchange Rate Effect are -$60000.0 (Q4 2025), $222000.0 (Q3 2025), and $8.8 million (Q2 2025).